Cardiff Oncology (NASDAQ:CRDF) Given New $10.00 Price Target at Piper Sandler

Cardiff Oncology (NASDAQ:CRDF) had its target price upped by Piper Sandler from $7.00 to $10.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other equities analysts also recently commented on the stock. HC Wainwright lowered their price objective on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Craig Hallum began coverage on Cardiff Oncology in a research report on Friday, September 6th. They set a “buy” rating and a $8.00 price target for the company.

Cardiff Oncology Stock Up 19.9 %

Shares of NASDAQ CRDF opened at $3.92 on Friday. The firm’s fifty day moving average is $2.89 and its 200 day moving average is $2.61. Cardiff Oncology has a 52 week low of $1.27 and a 52 week high of $6.42. The company has a market cap of $200.43 million, a price-to-earnings ratio of -4.17 and a beta of 1.89.

Insider Buying and Selling at Cardiff Oncology

In related news, Director Gary W. Pace bought 350,115 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was purchased at an average cost of $2.60 per share, with a total value of $910,299.00. Following the transaction, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 DIFC Ltd bought a new stake in Cardiff Oncology during the 2nd quarter valued at approximately $27,000. Ground Swell Capital LLC purchased a new position in shares of Cardiff Oncology in the 2nd quarter valued at approximately $38,000. Dimensional Fund Advisors LP boosted its position in shares of Cardiff Oncology by 34.4% during the second quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock valued at $42,000 after purchasing an additional 4,892 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Cardiff Oncology in the third quarter worth $64,000. Finally, Invst LLC bought a new position in Cardiff Oncology in the second quarter worth $74,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.